This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Best Growth Stocks to Buy for January 19th
by Zacks Equity Research
PFE, M, and AN made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 19, 2022
Why You Should Invest in Dividend Growth ETFs Now
by Neena Mishra
We highlight 3 ultra-cheap ETFs that focus on high quality dividend payers
Best Growth Stocks to Buy for January 18th
by Zacks Equity Research
BERY, M, and PFE made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 18, 2022
Arena (ARNA) Stock Up in 6 Months on PFE Merger Deal & Pipeline
by Zacks Equity Research
Arena Pharmaceuticals' (ARNA) potential acquisition by Pfizer to enable it to advance the development of its pipeline, especially the company's lead candidate, etrasimod, for ulcerative colitis.
AstraZeneca (AZN) Enhertu sBLA Receives FDA Priority Tag
by Zacks Equity Research
AstraZeneca's (AZN) sBLA seeks approval of Enhertu for unresectable and/or metastatic HER2-positive metastatic breast cancer previously treated with an anti-HER2-based regimen.
5 Low-Beta High-Yielding Stocks to Buy in a Capricious Market
by Nalak Das
We have narrowed our search to five large-cap low-beta stocks with a solid dividend yield. These are: PFE, BAX, IBKR, PSA and CUBE.
Zacks Industry Outlook Highlights: Roche, Pfizer, AbbVie and Merck
by Zacks Equity Research
Roche, Pfizer, AbbVie and Merck are highlighted in this Industry Outlook article.
AbbVie's (ABBV) Rinvoq Gets FDA Nod for Atopic Dermatitis
by Zacks Equity Research
FDA approves AbbVie's (ABBV) Rinvoq for the treatment of moderate to severe atopic dermatitis in adults and children aged 12 and above. This is the third indication for Rinvoq in the United States.
Glaxo (GSK) Rejects Unilever's $68B Bid for Consumer Business
by Zacks Equity Research
Glaxo (GSK) rejects an offer from Unilever to acquire its consumer business worth 50 billion pounds ($68 billion). However, Unilever is likely to pursue the acquisition of the business.
Pfizer's (PFE) Cibinqo Gets FDA Nod for Atopic Dermatitis
by Zacks Equity Research
After a series of delays, Pfizer's (PFE) oral JAK inhibitor, Cibinqo (abrocitinib), gets approval for treating adults with atopic dermatitis in the United States.
4 Large-Cap Drugmaker Stocks to Watch Despite Omicron Woes
by Kinjel Shah
Drug/biotech and medical device companies are likely to remain in the spotlight in 2022. Among the large drugmakers Roche (RHHBY), Pfizer (PFE), AbbVie (ABBV), and Merck (MRK) are worth retaining in your portfolio.
The Zacks Analyst Blog Highlights: Pfizer (PFE), Beam Therapeutics, AbbVie, Merck and Glaxo
by Zacks Equity Research
Pfizer (PFE), Beam Therapeutics, AbbVie, Merck and Glaxo are highlighted in this analyst blog article.
Best Growth Stocks to Buy for January 17th
by Zacks Equity Research
PFE, M, and ACN made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 17, 2022
AstraZeneca (AZN) COVID-19 Booster Dose Useful Against Omicron
by Zacks Equity Research
Data from multiple studies support the use of AstraZeneca's (AZN) COVID vaccine booster against several variants of concern, including Omicron.
Zacks Value Trader Highlights: Exxon Mobil, Pfizer, CF Industries, Comerica, and Crocs
by Zacks Equity Research
Zacks Value Trader Highlights: Exxon Mobil, Pfizer, CF Industries, Comerica, and Crocs.
Ascendis' (ASND) TransCon hGH Gets EU Nod for Pediatric GHD
by Zacks Equity Research
Ascendis Pharma (ASND) gets nod in Europe for TransCon hGH for the treatment of pediatric growth hormone deficiency.
Pharma Stock Roundup: PFE's Research Deal With BEAM & Other Updates
by Kinjel Shah
Pfizer (PFE) inks research collaboration with Beam Therapeutics. Merck's (MRK) Keytruda improves survival in adjuvant lung cancer
The Value Investor's Secret Weapon: The PEG Ratio
by Tracey Ryniec
Why not buy top value stocks that also have growth?
Ocugen's (OCGN) COVID-19 Booster Effective Against Omicron
by Zacks Equity Research
Ocugen's (OCGN) India-based partner announces robust neutralizing antibody responses against Omicron and Delta variants, following the administration of the booster dose of COVID-19 vaccine, Covaxin.
Pfizer's (PFE) Prevnar 20 Plus COVID Vaccine Study Succeeds
by Zacks Equity Research
Pfizer's (PFE) data from a phase III study showed that its COVID-19 vaccine and pneumococcal conjugate vaccine, Prevnar-20 can be given at the same time.
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $56.65, moving -0.07% from the previous trading session.
Molecular (MOLN), Novartis Post Positive Data From COVID-19 Drug
by Zacks Equity Research
Molecular (MOLN) and Novartis announce encouraging data from a phase II study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19. Shares of Molecular Partners gain on the same.
Merck (MRK) Keytruda Betters Survival in Adjuvant Lung Cancer
by Zacks Equity Research
Merck's (MRK) phase III study evaluating Keytruda for adjuvant stage IB-IIIA non-small cell lung cancer (NSCLC) meets one of its dual primary endpoints of disease-free survival (DFS).
Pfizer (PFE) Partners Beam Therapeutics for Rare Disease Drugs
by Zacks Equity Research
Pfizer (PFE) collaborates with Beam Therapeutics (BEAM) to advance the next generation of gene-editing therapies.
Moderna (MRNA) Up on Plans to Get Omicron Booster Ready in 2022
by Zacks Equity Research
Moderna (MRNA) plans to begin clinical development of its Omicron-specific variant vaccine early in 2022 and expects to make it available for the public in the fall of 2022.